$JAGX News

Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Prepared Remarks Transcript

Jaguar Health Reports Q2 2026 Results: Full Earnings Call Transcript

Jaguar Health Q2 EPS $(15.70) Up From $(358.94) YoY, Sales $1.225M Down From $2.979M YoY

Jaguar Health’s Napo Pharma Satisfies Conditions Required To Receive Payment Of Non-Dilutive $2M Holdback Amount From Future Pak Related To US Commercial Licensing Agreement

Jaguar Health Says Findings Of Exploratory Surveys Of Dog Owners And Veterinary Oncologists Support Commercial Opportunity For Neonorm Dog, New Extension Of Jaguar's Neonorm Franchise

Jaguar Health Portfolio Company Napo Pharmaceuticals Provides Its Novel Crofelemer Powder To Treat Intestinal Failure From Microvillus Inclusion Disease In The EU For Compassionate Use

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Health Submits New Animal Drug Application To FDA For Veterinary Medicine For Full Approval Of Crofelemer To Treat Chemotherapy-Induced Diarrhea In Dogs

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program

Jaguar Health Board Initiates Process To Mull, Review Strategic Options

Jaguar Health Board Initiates Review Of Strategic Alternatives To Maximize Shareholder Value, Aligned With Anticipated NDA Filing For Crofelemer Candidate In Rare Intestinal Failure Diseases

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention

Jaguar Health Announces Data From Preclinical Study Initiates By Magdalena Biosciences Shows Novel Extract Derived From Coca Plant Leaves Stops Weight Gain In Mice

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

Jaguar Health CEO To Present At Life Sciences Virtual Investor Forum

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

Jaguar Health Inc (JAGX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...

Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript